Anti-inflammatory therapies in sepsis and septic shock

Bibliography

• FREEMAN BD, NATANSON C: Clinical trials in sepsis and septic shock. Corr. Opin. Grit. Care (1995) 1:349–357.
   Google Scholar
• •Recent review and analyses of clinical trials examining anti-inflammatory therapies in sepsis.
   Google Scholar
• FREEMAN BD, EICHACKER PQ, NATANSON C: The role of inflammation in sepsis and septic shock: a meta-analysis of both clinical and pre-clinical trials of anti-inflammatory therapies. In: Inflammation: Basic Principles and Clinical Correlates. 3 ed. Gallin J, Snyderman R, (Eds.) Lippincott Williams & Wilkins, Philadelphia, USA (1999) :965–976.
   Google Scholar
• •Recent review and analyses of clinical trials examining anti-inflammatory therapies in sepsis.
   Google Scholar
• ZENI F, FREEMAN BD, NATANSON C: Anti-inflammatory therapies to treat sepsis and septic shock: a reassess-ment. Grit. Care Med. (1997) 25:1095–1100.
   PubMed Web of Science ®Google Scholar
• •Recent review and analyses of clinical trials examining anti-inflammatory therapies in sepsis.
   Google Scholar
• QUEZADO ZMN, BANKS SM, NATANSON C: New strategies for combating sepsis: the magic bullets missed the mark.but the search continues. Trends Biotechnol (1995) 13:56–63.
   PubMed Web of Science ®Google Scholar
• •Recent review and analyses of clinical trials examining anti-inflammatory therapies in sepsis.
   Google Scholar
• NATANSON C, ESPOSITO C, BANKS S: The siren's song of confirmatory sepsis trials: selection bias and sampling errors. Grit. Care Med. (1998) 26:1927–1931.
   PubMed Web of Science ®Google Scholar
• •Recent review and analyses of clinical trials examining anti-inflammatory therapies in sepsis.
   Google Scholar
• SEVRANSKY JE, NATANSON C: Published clinical trials in sepsis: an update. Sepsis (1999) 3:11–19.
   Google Scholar
• •Recent review and analyses of clinical trials examining anti-inflammatory therapies in sepsis.
   Google Scholar
• DEPIETRO MR, NATANSON C: Sepsis trials: what have we learned? Clin. Pulmonary Med. (1999) 6:367–377.
   Google Scholar
• •Recent review and analyses of clinical trials examining anti-inflammatory therapies in sepsis.
   Google Scholar
• WEIL MH, MACLEAN CD, FISSEHER MB, SPINK WW: Studies of the circulatory changes in the dog produced by endotoxin from Gram-negative micoorganisms. J. Clin. Invest. (1956) 35:1191–1198.
   PubMed Web of Science ®Google Scholar
• NATANSON C, EICHENHOLZ PW, DANNER RL et al.: Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock. J. Exp. Med. (1989) 169:823–832.
   PubMed Web of Science ®Google Scholar
• WAAGE A, ESPEVIK T: Interleukin-1 potentiates the lethal effects of tumor necrosis factor/cachectin in mice. J. Exp. Med. (1988) 167:1987–1992.
   PubMed Web of Science ®Google Scholar
• OKUSAWA S, GEFAND JA, IKEJIMA T, CONNOLLY RJ, DINARELLO CA: Interleukin-1 induces a shock like state in rabbits: synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J. Clin. Invest. (1988) 81:1162–1172.
   PubMed Web of Science ®Google Scholar
• OHLSSON K, BJQRK, BERGENFELDT M, HAGEMAN R, THOMPSON RC: Interleukin-1 receptor antagonist reduces mortality from endotoxin shock. Nature (1990) 348:550–552.
   PubMed Web of Science ®Google Scholar
• WAKABAYASHI G, GELFAND JA, BURKE JF, THOMPSONRC, DINARELLO CA: A specific receptor antagonist for Interleukin-1 prevents Escherichia coli-induced shock in rabbits. FASEB (1991) 5:338–343.
   PubMed Web of Science ®Google Scholar
• FISHER E, MARANO MA, VAN ZEE KJ et al.: Interleukin-1receptor blockade improves survival and hemody-namic performance in Escherichia coil septic shock, but fails to alter host responses to sublethal endotoxemia. j Clin. Invest. (1992) 89:1551–1557.
   Google Scholar
• BEUTLER B, MILSARK IW, CERAMI AC: Passive immuni-zation against cachetin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science (1985) 229:869–871.
   PubMed Web of Science ®Google Scholar
• SUITTERS AJ, FOULKES R, OPAL SM et al.: Differentialeffect of isotype on efficacy of anti-tumor necrosis factor-a chimeric antibodies in experimental septic shock. J. Exp. Med (1994) 179:849–856.
   PubMed Web of Science ®Google Scholar
• BAGBY GJ, PLESSALA KJ, WILSON LA, THOMPSON JJ, NELSON S: Divergent efficacy of antibody to tumor necrosis factor-a in intravascular and peritonitis models. J. Infect. Dis. (1991) 163:83–88.
   PubMed Web of Science ®Google Scholar
• MATHISON JC, WOLFSON E, ULEVITCH RJ: Participationof tumor necrosis factor in the mediation of Gram negative bacterial lipopolysaccharide-induced injury in rabbits. J. Clin. Invest. (1988) 81:1925–1937.
   PubMed Web of Science ®Google Scholar
• FIEDLER VB, LOOF I, SANDER E, VOEHRINGER V,GALANOS C, FOURNAL MA: Monoclonal antibody to tumor necrosis factor-a prevents lethal endotoxinsepsis in adult rhesus monkeys. J. Lab. Clin. Merl. (1992) 120:574–588.
   PubMed Web of Science ®Google Scholar
• EMERSON TE, LINDSEY DC, JESMONK GJ, DUERR ML, FOURNEL MA: Efficacy of monoclonal antibody against tumor necrosis factor-a in an endotoxemic baboon model. Circ. Shock (1992) 38:75–84.
   PubMedGoogle Scholar
• ESKANDARI MK, BOLGOS G, MILLER C, NGUYEN DT, DEFORGE LE, REMICK DG: Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. J. Immunol (1992) 9:2724–2730.
   Google Scholar
• SILVA AT, BAYSTON KF, COHEN J: Prophylactic andtherapeutic effects of a monoclonal antibody to tumor necrosis factor-a in experimental Gram-negative shock. J. Infect. Dis. (1990) 162:421–427.
   PubMed Web of Science ®Google Scholar
• JESMOK G, LINDSEY C, DUERR M, FOURNEL M, EMERSONT: Efficacy of monoclonal antibody against human recombinant tumor necrosis factor in E. co/i-challenged swine. Am] Path. (1992) 141:1197–1207.
   PubMed Web of Science ®Google Scholar
• HINSHAW LB, TEKAMP-OLSON P, CHANG ACK et al.:Survival of primates in LDtho septic shock following therapy with antibody to tumor necrosis factor (TNF-a). Circ. Shock (1990) 30:279–292.
   PubMedGoogle Scholar
• TRACEY KJ, FONG Y, HESSE DG et al.: Anti-cachectin/TNF monoclonal antibodies prevent septic shock curing lethal bacteremia. Nature (1987) 330:662–664.
   PubMed Web of Science ®Google Scholar
• HINSHAW LB, EMERSON TE, TAYLOR FB et al.: Lethal Staphylococcus aureus-induced shock in primates: prevention of death with anti-TNF antibody. J. Trauma (1992) 33:568–573.
   PubMed Web of Science ®Google Scholar
• OPAL SM, CROSS AS, KELLY NM et al.: Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa. j Infect. Dis. (1990) 161:1148–1152.
   PubMed Web of Science ®Google Scholar
• NATANSON C, HOFFMAN WD, SUFFREDINI AF, EICHACKER PQ, DANNER RL: Selected treatment strate-gies for septic shock based on proposed mechanisms of pathogenesis. Ann. Internal Med. (1994) 120:771–783.
   PubMed Web of Science ®Google Scholar
• •A review of the pathogenesis of sepsis and septic shock as a basis for developing anti-inflammatory therapies.
   Google Scholar
• SACKS MS: Fulminating septicemia associated with purpura and bilateral adrenal hemorrhage (Waterhouse-Friderichsen Syndrome); Report of two cases with review of the literature. Ann. Internal Med. (1936) 1105–1114.
   Google Scholar
• SWINGLE WW, PFIFFNER JJ: An aqueous extract of the suprarenal cortex which maintains the life of bilater-ally adrenalectomized cats. Science (1930) 71:321–322.
   PubMedGoogle Scholar
• HARTMAN FA, SCOTT WJM: Protection of adrenalecto-mized animals against bacterial intoxication by an extract of the adrenal cortex. J. Exp. Med. (1932) 55:63–69.
   PubMedGoogle Scholar
• MELBY JC, SPINK WW: Comparative studies of adrenalcortical function and cortisol metabolism in healthy adults and in patients with shock due to infection. J. Clin. Invest. (1958) 1791–1798.
   Google Scholar
• ROBSON HG, CLUFF LE: Experimental Pneumococcal and Staphylococcal sepsis: the effects of hydrocorti-sone and phenoxybenzamine upon mortality rate. J. Clin. Invest. (1966) 45:1432.
   Web of Science ®Google Scholar
• FABIAN TC, PATTERSON R: Steroid therapy in septic shock. Survival study in a laboratory model. Am. Surgeon (1982) 48:614–617.
   PubMed Web of Science ®Google Scholar
• HINSHAW LB, BELLER-TODD BK, ARCHER LT, BENJAMEN B, FLOURNOY DJ, PASSEY R: Effectiveness of steroid antibiotic treatment in primates administered LDioo Eschericia colt. Ann. Surgery (1981) 194:51–56.
   PubMed Web of Science ®Google Scholar
• HINSHAW LB, ARCHER LT, BELLER-TODD BK, BENJAMEN DJ, FLOURNOY DJ, PASSEY R: Survival of primates in lethal septic shock following delayed treatment with steroid. Circ. Shock (1981) 8:291–300.
   PubMedGoogle Scholar
• HINSHAW LB, FLOURNOY DJ, ARCHER LT, WHITE GL, PHILLIPS RW: Recovery from lethal Escherichia coli shock. Surg. Gynecol. Obst. (1979) 545–553.
   PubMedGoogle Scholar
• HINSHAW LB, ARCHER LT, BELLER-TODD BK et al: Survival of primates in LD100 septic shock following steroid/antibiotic therapy. J. Surg. Res. (1980) 151–170.
   PubMed Web of Science ®Google Scholar
• WHITE GL, ARCHER LT, BELLER-TODD BK, HINSHAW LB: Increased survival with methylprednisolone treatment in canine endotoxin shock. J. Surg. Res. (1978) 25:357–364.
   PubMed Web of Science ®Google Scholar
• BELLER-TODD BK, ARCHER LT, PASSEY R, FLOURNOY DJ, HINSHAW LB: Effectiveness of modified steroid-antibiotic therapies for lethal sepsis in the dog. Arch. Surg. (1983) 118:1293–1299.
   PubMed Web of Science ®Google Scholar
• BENNETT IL, FINLAND M, HAMBORGER M, KASS EH, LEPPER M, WAISBREN BA: The effectiveness of hydrocortisone in the management of severe infection. J. Am. Med. Ass. (1963) 183:462–465.
   Web of Science ®Google Scholar
• LUCE JM, MONTGOMERY AB, MARKS JD, TURNER J, METZCA, MURRAY JF: Ineffectiveness of high-dose methyl-prednisolone in preventing parenchymal lung injury and improving mortality in patients with septic shock. Am. Rev. Resp. Dis. (1988) 138:62–68.
   PubMed Web of Science ®Google Scholar
• THE VETERANS ADMINISTRATION SYSTEMIC SEPSIS CO-OPERATIVE STUDY GROUP: Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl. J. Med. (1987) 317:659–665.
   PubMed Web of Science ®Google Scholar
• BONE RC, FISHER CJ, CLEMMER TP et al: A controlledtrial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl. J. Med. (1987) 317:653–658.
   PubMed Web of Science ®Google Scholar
• SPRUNG CL, CARALIS PV, MARCIAL EH et al: The effects of high-dose corticosteroids in patients with septic shock. N Engl. J. Med. (1984) 311:1137–1143.
   PubMed Web of Science ®Google Scholar
• THOMPSON WL, GURLEY HT, LUTZ BA, JACKSON DL, KVOLS LK, MORRIS IA: Inefficacy of glucocorticoids in shock (double-blind study). Clin. Research. (1976) 24:258A (Abstract).
   Google Scholar
• LUCAS CE, LEDGERWOOD AM: The cardiopulmonary response to massive doses of steroids in patients with septic shock. Arch. Surg. (1984) 119:537–541.
   PubMed Web of Science ®Google Scholar
• SCHUMER W: Steroids in the treatment of clinical septic shock. Ann. Surg. (1976) 184:333–339.
   PubMed Web of Science ®Google Scholar
• KLASTERSKY J, CAPPELL R, DEBUSSCHER L: Effectiveness of betamethasone in management of severe infections. N Engl. J. Med (1971) 284:1248–1250.
   PubMed Web of Science ®Google Scholar
• CRONIN L, COOK DJ, CARLET J et al.: Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit. Care Med (1995) 23:1430–1439.
   PubMed Web of Science ®Google Scholar
• LEFERING R, NEUGEBAUER EAM: Steroid controversy in sepsis and septic shock: a meta-analysis. Crit. Care Med. (1995) 23:1294–1303.
   PubMed Web of Science ®Google Scholar
• •Recent meta-analyses of glucocorticoid trials in sepsis.
   Google Scholar
• ROTHWELL PM, UDWADIA ZF, LAWLER PG: Cortisol response to corticotropin and survival in septic shock. Lancet (1991) 337:1230–1231.
   Web of Science ®Google Scholar
• MORAN JL, CHAPMAN MJ, O'FATHARTAIGH MS, PEISACH AR, PANNALL PR, LEPPARD P: Hypocortisolaemia and adrenocortical responsiveness at onset of septic shock. Intensive Care Med. (1994) 20:489–495.
   PubMed Web of Science ®Google Scholar
• SONI A, PEPPER GM, WYRWINSKI PM et al: Adrenal insufficiency occurring during septic shock: incidence, outcome and relationship to peripheral cytokine levels. Am. J. Med. (1995) 98:266–271.
   PubMed Web of Science ®Google Scholar
• BOLLAERT PE, CHARPENTIER C, LEVY B, DEBOUVERIE M, AUDIBERST G, LARCAN A: Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit. Care Med. (1998) 26:645–650.
   PubMed Web of Science ®Google Scholar
• BRIEGEL J, FORST H, HALLER M et al.: Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single center study. Crit. Care Med. (1999) 27:723–732.
   PubMed Web of Science ®Google Scholar
• CHAWLA K, KUPFER Y, GOLDMAN I, TESSLER S. Hydrocortisone reverses refractory septic shock. Crit. Care Med. (1999) 27:A33 (Abstract).
   Google Scholar
• •Recent trials demonstrating the efficacy of glucocorticoids in sepsis.
   Google Scholar
• ZIEGLER EJ, MCCUTCHAN JA, FIERER J et al: Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Esherichia coli. N Engl. J. Med (1982) 307:1225–1230.
   PubMed Web of Science ®Google Scholar
• MCCUTCHAN JA, WOLF JL, ZIEGLER EL, BRAUDE Al: Ineffectiveness of single-dose human antiserum to core glycolipid (Esherichia coliJ5) for prophylaxis of bacteremic, Gram-negative infection in patients with prolonged neutropenia. Schweizerische Medezinische Wochenschrift.J. Suisse de Medecine. (1983) 113 (Suppl.) :40–55.
   Google Scholar
• BAUMGARTNER JD, GLAUSER MP, MCCUTCHAN JA et al.: Prevention of Gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet (1985) 11:59–63.
   Google Scholar
• THE J5 STUDY GROUP: Treatment of severe infectiouspurpura in children with human plasma from donors immunized with Esherichia coli 15: a prospective double-blind study. J. Infect. Dis. (1992) 165:695–701.
   PubMedGoogle Scholar
• CALANDRA T, GLAUSER MP, SCHELLEKENS J, VERHOEF JAND THE SWISS-DUTCH J5 IMMUNOGLOBULIN STUDY GROUP: Treatment of Gram-negative septic shock with human IgG antibody to Escherichia coliJ5: a prospec-tive, double-blind, randomized trial. J. Infect. Dis. (1988) 158:312–319.
   PubMed Web of Science ®Google Scholar
• THE INTRAVENOUS IMMUNOGLOBULIN COLLABORA-TIVE STUDY GROUP: Prophylactic intravenous admini-stration of standard immune globulin as compared with core-lipopolysaccharide immune globulin in patients at high risk of postsurgical infections. N Engl. J. Med. (1992) 327:234–240.
   PubMed Web of Science ®Google Scholar
• GREENMAN RL, SCEIN RMH, MARTIN MA et al: A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. J. Am. Med. Ass. (1991) 266:1097–1102.
   PubMed Web of Science ®Google Scholar
• BONE RC, BALK RA, FEIN AM et al.: A second largecontrolled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. Crit. Care Med. (1995) 23:994–1006.
   PubMed Web of Science ®Google Scholar
• ZIEGLER EJ, FISHER CJ, SPRUNG CL et al.: Treatment ofGram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. N Engl. J. Med. (1991) 324:429–436.
   PubMed Web of Science ®Google Scholar
• MCCLOSKY RV, STRAUBE RC, SANDERS C, SMITH SM, SMITH CR, THE CHESS TRIAL STUDY GROUP: Treatment of septic shock with human monoclonal antibody HA-1A. Ann. Int. Med. (1994) 121:1–5.
   PubMed Web of Science ®Google Scholar
• DANNER RL, NATANSON C: Endotoxin: a mediator ofand potential therapeutic target for septic shock. In: Bacterial Toxins and Virulence Factors in Disease. Moss J, Iglewski B, Vaughan M, Tu AT, (Eds.) Marcel Dekker, Inc. New York, USA (1995):590–617.
   Google Scholar
• HELMERHORST EJ, MAASKANT JJ, APPELMELK BJ: Anti-lipid A monoclonal antibody Centoxin (HA-1A) binds to a wide variety of hydrophobic ligands. Infect. Immun. (1998) 66:870–873.
   PubMed Web of Science ®Google Scholar
• KAY CA: Can better measures of cytokine responses be obtained to guide cytokine inhibition. Knoll AG, Ludwigshafen, Germany. Presentation and handout. Cambridge Health Institutes' Designing Better Drugs and Clin. trials for Sepsis/SIRS: Reducing mortality to patients and suppliers. Washington DC, USA February 20–21, (1996).
   Google Scholar
• REINHART K, WIEGAND-LOHNERT GF, KAUL M et al.: Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit. Care Merl. (1996) 24:733–742.
   PubMed Web of Science ®Google Scholar
• FISHER CJ, OPAL SM, DHAINAUT JF et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit. Care Med. (1993) 21:318–327.
   PubMed Web of Science ®Google Scholar
• DHAINAUT JFA, VINCENT JL, RICHARD C et al.: CPD571, a humanized antibody to human tumor necrosis factor-a: safety, pharmacokinetics, immune response and influence of the antibody on cytokine concentra-tions in patients with septic shock. Crit. Care Med. (1995) 23:1461–1499.
   PubMed Web of Science ®Google Scholar
• ABRAHAM E, WUNDERINK R, SILVERMAN H et al.: Efficacy and safety of monoclonal antibody to human tumor necrosis factor-a in patients with sepsis syndrome. J. Am. Med. Ass. (1995) 273:934–941.
   PubMed Web of Science ®Google Scholar
• COHEN J, CARLET J: INTERSEPT: an international,multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-a in patients with sepsis. Crit. Care Med. (1996) 26:1431–1440.
   Web of Science ®Google Scholar
• ABRAHAM E, ANZUETO A, GUITERREZ G: Double-blindrandomized controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet (1998) 351:929–933.
   PubMed Web of Science ®Google Scholar
• CLARK MA, PLANK LD, CONNOLLY AB: Effect of a chimeric antibody to tumor necrosis factor on cytokine and physiologic responses in patients with severe sepsis - a randomized clinical trial. Crit. Care Med (1998) 26:1650–1659.
   PubMed Web of Science ®Google Scholar
• FISHER CJ, AGOSTI JM, OPAL SM et al.: Treatment ofseptic shock with the tumor necrosis factor receptor:Fc fusion protein. N Engl. J. Med. (1996) 334:1697–1702.
   PubMed Web of Science ®Google Scholar
• ABRAHAM E: Immunomodulation therapy in sepsis: failure in clinical trials or critical thinking. Am. Thoracic Soc. (1998) 1:1 (Abstract).
   Google Scholar
• ABRAHAM E, GLAUSER MP, BUTLER T et al.: p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. J. Am. Merl. Ass. (1997) 277:1531–1538.
   PubMed Web of Science ®Google Scholar
• FISHER CJ, SLOTMAN GJ, OPAL SM et al.: Initial evalua-tion of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit. Care Med. (1994) 22:1–21.
   PubMed Web of Science ®Google Scholar
• FISHER CJ, DHAINAUT JF, OPAL SM et al.: Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. J. Am. Merl. Ass. (1994) 271:1836–1843.
   PubMed Web of Science ®Google Scholar
• OPAL SM, FISHER CJ, DHAINAUT JF: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a Phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit. Care Med. (1997) 25:1115–1124.
   PubMed Web of Science ®Google Scholar
• BERNARD GR, WHEELER AP, RUSSELL JA et al.:The effectsof ibuprofen on the physiology and survival of patients with sepsis. N Engli Med. (1997) 336:912–918.
   PubMed Web of Science ®Google Scholar
• HAUPT MT, JASTREMSKI MS, CLEMMER TP, METZ CA, GORIS GB, THE IBUPROFEN STUDY GROUP: Effect of ibuprofen in patients with severe sepsis: a randomized, double-blind, multicenter study. Crit. Care Med. (1991) 19:1339–1347.
   PubMed Web of Science ®Google Scholar
• BERNARD GR, REINES HD, HALUSHKA PV. Prostacyclin and thromboxane Ay formation is increased in human sepsis syndrome. Am. Rev. Respir. Dis. (1991) 144:1095–1101.
   Google Scholar
• RODELL TC, FOSTER C: Sepsis data show negative trend in second Phase II sepsis trial. Press Release: Cortech, Inc., 7000 North Broadway, Denver, CO 80821. 7–18–1995.
   Google Scholar
• FEIN AM, BERNARD GR, CRINER GJ et al.: Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, Deltbant (CP-0127). J. Am. Med. Ass. (1997) 277:482–487.
   PubMed Web of Science ®Google Scholar
• DHAINAUT JFA, TENAILLON A, TULZO YL et al.: Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Critical Care Medicine. (1994) 22:1720-1728 (Abstract).
   Google Scholar
• DHAINAUT JF, TENAILLON A, HEMMER M et al.: Confir-matory platelet-activating factor receptor antagonist trial in patients with severe Gram-negative bacterial sepsis: a Phase III, randomized, double-blind, placebo-controlled, multicenter trial. Crit. Care Med. (1998) 26:1963–1971.
   PubMed Web of Science ®Google Scholar
• ABRAHAM, E., GLAUSER, M. AND GELMONT, D. Ro 45–2081 (TNER55-1gG1) in the treatment of patients with severe sepsis and septic shock: preliminary results. 1-1-995. International Autumnal Thematic Meeting on Sepsis, Deauville, France, November 5–7, (1995).
   Google Scholar
• MIRA JP, CARIOU A, GRALL F et al.: Association of TNE2, a TNF promotor polymorphism, with septic shock susceptibility and mortality - a multicenter study. J. Am. Med. Ass. 282(6)561–568.
   Google Scholar
• KUMAR A, SHORT J, PARRILLO JE: Genetic factors in septic shock. J. Am. Med. Ass. (1999) 282:579–581.
   Web of Science ®Google Scholar
• STUBER F, PETERSON M, BOKELMANN F, SCHADE U: A genomic polymorhpism with in the tumor necrosis factor locus influences plasma tumor necrosis factor concentrations and outcome of patients with severe sepsis. Grit. Care Med. (1996) 24:381–384.
   PubMed Web of Science ®Google Scholar
• •Recent reports examining the genetic susceptibility to sepsis.
   Google Scholar
• GROVER R, LOPEZ A, LORENTE J et al.: Multi-center, randomized, placebo-controlled, double blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock. Crit. Care Med. (1998) 26:A33 (Abstract).
   Google Scholar
• GROVER R, ZACCARDELLI D, COLICE G et al.: An open-label dose escalation study of the nitric oxide synthase inhibitor, N-methyl-L-arginine hydrochlo-ride (546C88), in patients with septic shock. Crit. Care Med. (1999) 27:913–922.
   PubMed Web of Science ®Google Scholar
• DAVID SA, SILVERSTEIN R, AMURA CR, KIELIAN T, MORRISON DC: Lipopolyamines: novel antiendotoxin compounds that reduce mortality in experimental sepsis caused by Gram-negative bacteria. Antimicrob. Agents Chemother. (1999) 43:912–919.
   PubMed Web of Science ®Google Scholar
• MARRA MN, GRAIG G, GRIFFITH JE, SNABLE J, SCOTT W: Bactericidal/permeability-increasing protein has endotoxin-neutralizing activity. J. Immunol. (1990) 144:662–666.
   PubMed Web of Science ®Google Scholar
• SERVICE RF: Microchip arrays put DNA on the spot.Science (1998) 282:396–399.
   PubMed Web of Science ®Google Scholar